Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study. - UroToday

 To evaluate the clinical therapeutic response of PSMA targeted radioligand therapy with 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. The current study analyzed disease-related quality of life (QoL) in patients undergoing PSMA therapy with a special focus on the association with simultaneous PSA response.

 Thirty patients (age range 50-87 years, median 73.5 years) undergoing 177Lu-PSMA-617 therapy from 2014 to 2016 at our institution were included in this pilot study. Health-related QoL was assessed by EORTC QLQ-C30 questionnaire filled in at baseline and two months after initializing the PSMA-therapy. The treatment response was evaluated under three categories with regard to changes in (a) global health status and other functional scales, (b) disease-related symptoms, and (c) effects of PSA values.

 Most patients underwent three treatment cycles (n = 12); at least 2 cycles (n = 6) or at most 8 cycles (n = 1) were performed. Out of 30 cases, PSA response after the first cycle was observed in 73 % (n = 22). Compared to baseline, QoL was significantly improved at 2-month follow-up revealing increase in global health status (p = 0.025), role functioning (p = 0.017) and emotional functioning (0.010), and decrease in pain (p = 0.033). Global health status variation can be explained up to 20.5 % by response in PSA (p = 0.012), this improved with PSA reduction.

 PSMA radioligand therapy seems to be an effective treatment option of metastatic castration-resistant prostate cancer patients as it improves their QoL in terms of increasing global health and mitigation of disease-related pain.

Nuklearmedizin. Nuclear medicine. 2020 Aug 21 [Epub ahead of print]

Milka Marinova, Reza Alamdar, Hojjat Ahmadzadehfar, Markus Essler, Ulrike Attenberger, Martin Mücke, Rupert Conrad

Department of Diagnostic and Interventional Radiology, University Hospital Bonn, Germany., Department of Nuclear Medicine, University Hospital Bonn, Germany., Center for Rare Diseases Bonn (ZSEB), University Hospital of Bonn, Germany., Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Bonn, Germany.



Comments

Popular posts from this blog

Q&A

Sentinel lymph node biopsy: What cancer patients should know

I Wish I Didn't Need an Oncologist at All, But I'm Thankful for the One ...